Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results, Beats Estimates By $0.15 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX) announced its quarterly earnings data on Tuesday. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15, Briefing.com reports. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the firm earned ($0.73) earnings per share.

Syndax Pharmaceuticals Trading Up 0.8 %

NASDAQ SNDX traded up $0.18 during trading hours on Thursday, hitting $21.53. The company’s stock had a trading volume of 143,844 shares, compared to its average volume of 1,060,669. The company has a market capitalization of $1.83 billion, a PE ratio of -6.32 and a beta of 0.92. Syndax Pharmaceuticals has a 52 week low of $13.14 and a 52 week high of $25.34. The company’s 50-day simple moving average is $19.06 and its two-hundred day simple moving average is $20.32.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. UBS Group assumed coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective for the company. Citigroup upped their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Barclays increased their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. reduced their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Bank of America increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $36.10.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).